JP2022526553A - 炎症性障害の治療のための新規化合物及びその医薬組成物 - Google Patents

炎症性障害の治療のための新規化合物及びその医薬組成物 Download PDF

Info

Publication number
JP2022526553A
JP2022526553A JP2021557759A JP2021557759A JP2022526553A JP 2022526553 A JP2022526553 A JP 2022526553A JP 2021557759 A JP2021557759 A JP 2021557759A JP 2021557759 A JP2021557759 A JP 2021557759A JP 2022526553 A JP2022526553 A JP 2022526553A
Authority
JP
Japan
Prior art keywords
independently selected
compound
substituted
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021557759A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022526553A5 (https=
Inventor
マンモリティ オスカー
クリストフ ザビエル ブリス レジナルド
ジョン ロバート ニューサム グレゴリー
ジルス バベル マリエール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
Original Assignee
Galapagos NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV filed Critical Galapagos NV
Publication of JP2022526553A publication Critical patent/JP2022526553A/ja
Publication of JP2022526553A5 publication Critical patent/JP2022526553A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021557759A 2019-03-29 2020-03-24 炎症性障害の治療のための新規化合物及びその医薬組成物 Pending JP2022526553A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1904375.1 2019-03-29
GBGB1904375.1A GB201904375D0 (en) 2019-03-29 2019-03-29 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
PCT/EP2020/058061 WO2020200898A1 (en) 2019-03-29 2020-03-24 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Publications (2)

Publication Number Publication Date
JP2022526553A true JP2022526553A (ja) 2022-05-25
JP2022526553A5 JP2022526553A5 (https=) 2023-04-06

Family

ID=66442789

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021557759A Pending JP2022526553A (ja) 2019-03-29 2020-03-24 炎症性障害の治療のための新規化合物及びその医薬組成物

Country Status (14)

Country Link
US (1) US20220296573A1 (https=)
EP (1) EP3947374A1 (https=)
JP (1) JP2022526553A (https=)
KR (1) KR20210143905A (https=)
CN (1) CN113677678A (https=)
AU (1) AU2020252900A1 (https=)
BR (1) BR112021019099A2 (https=)
CA (1) CA3134732A1 (https=)
GB (1) GB201904375D0 (https=)
IL (1) IL286688A (https=)
MX (1) MX2021011574A (https=)
PH (1) PH12021552377A1 (https=)
SG (1) SG11202110643YA (https=)
WO (1) WO2020200898A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA54755A (fr) * 2019-01-18 2021-11-24 Biogen Ma Inc Dérivés d'imidazo[1,2-a]pyridinyle servant d'inhibiteurs d'irak4
GB201904373D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders
GB201904374D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compunds and pharmaceutical composistions thereof for the treatment of inflammatory disorders
KR20230059584A (ko) 2021-10-26 2023-05-03 주식회사 엘지에너지솔루션 전극 조립체의 제조방법
WO2023098857A1 (zh) * 2021-12-03 2023-06-08 武汉人福创新药物研发中心有限公司 Irak4抑制剂及其用途

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016928A1 (ja) * 2003-08-15 2005-02-24 Banyu Pharmaceutical Co., Ltd. イミダゾピリジン誘導体
WO2005108399A1 (ja) * 2004-05-10 2005-11-17 Banyu Pharmaceutical Co., Ltd. イミダゾピリジン化合物
WO2018060174A1 (de) * 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Substituierte benzimidazole, pharmazeutische präparate diese enthaltend, sowie deren verwendung zur herstellung von arzneimitteln
WO2018060072A1 (de) * 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Neue substituierte benzimidazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
WO2020035020A1 (zh) * 2018-08-17 2020-02-20 浙江海正药业股份有限公司 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途
WO2020200900A1 (en) * 2019-03-29 2020-10-08 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2020200899A1 (en) * 2019-03-29 2020-10-08 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
JP2022517410A (ja) * 2019-01-18 2022-03-08 バイオジェン・エムエイ・インコーポレイテッド イミダゾ［１，２－ａ］ピリジニル誘導体及び疾患の処置におけるその使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9169260B2 (en) * 2011-03-22 2015-10-27 Merck Sharp & Dohme Corp. Amidopyrazole inhibitors of interleukin receptor-associated kinases
RU2675818C2 (ru) * 2013-03-14 2018-12-25 Галапаго Нв Новые соединения и фармацевтические композиции, их содержащие, для лечения воспалительных расстройств
EP3092226B1 (en) * 2014-01-10 2019-03-13 Aurigene Discovery Technologies Limited Indazole compounds as irak4 inhibitors
CN108473498B (zh) * 2015-12-22 2021-11-02 豪夫迈·罗氏有限公司 作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016928A1 (ja) * 2003-08-15 2005-02-24 Banyu Pharmaceutical Co., Ltd. イミダゾピリジン誘導体
WO2005108399A1 (ja) * 2004-05-10 2005-11-17 Banyu Pharmaceutical Co., Ltd. イミダゾピリジン化合物
WO2018060174A1 (de) * 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Substituierte benzimidazole, pharmazeutische präparate diese enthaltend, sowie deren verwendung zur herstellung von arzneimitteln
WO2018060072A1 (de) * 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Neue substituierte benzimidazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
WO2020035020A1 (zh) * 2018-08-17 2020-02-20 浙江海正药业股份有限公司 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途
JP2022517410A (ja) * 2019-01-18 2022-03-08 バイオジェン・エムエイ・インコーポレイテッド イミダゾ［１，２－ａ］ピリジニル誘導体及び疾患の処置におけるその使用
WO2020200900A1 (en) * 2019-03-29 2020-10-08 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2020200899A1 (en) * 2019-03-29 2020-10-08 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Also Published As

Publication number Publication date
AU2020252900A1 (en) 2021-11-25
SG11202110643YA (en) 2021-10-28
PH12021552377A1 (en) 2022-10-03
US20220296573A1 (en) 2022-09-22
KR20210143905A (ko) 2021-11-29
MX2021011574A (es) 2021-10-13
CN113677678A (zh) 2021-11-19
WO2020200898A1 (en) 2020-10-08
GB201904375D0 (en) 2019-05-15
EP3947374A1 (en) 2022-02-09
BR112021019099A2 (pt) 2021-11-30
CA3134732A1 (en) 2020-10-08
IL286688A (en) 2021-10-31

Similar Documents

Publication Publication Date Title
JP6745856B2 (ja) Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体
CN113924146B (zh) 用于治疗疾病的新化合物及其药物组合物
AU2018374456B2 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
TWI542588B (zh) 新穎雜環化合物
JP2022526553A (ja) 炎症性障害の治療のための新規化合物及びその医薬組成物
JP6771464B2 (ja) Ｃｂｐおよび／またはｅｐ３００インヒビターとしての、４，５，６，７−テトラヒドロ−１ｈ−ピラゾロ［４，３−ｃ］ピリジン−３−アミン化合物
JP2022526364A (ja) 炎症性障害の治療のための新規化合物及びその医薬組成物
JP2021527106A (ja) 新規化合物及び疾患の治療のためのその医薬組成物
JP6472454B2 (ja) 炎症性疾患治療のためのベンゾイミダゾール誘導体及びその医薬組成物
KR20180118752A (ko) 섬유증의 치료를 위한 신규 화합물 및 그의 약학 조성물
JP7600119B2 (ja) アデノシン受容体アンタゴニストとしてのチアゾロピリジン誘導体
JP2022526176A (ja) 炎症性障害の治療のための新規化合物及びその医薬組成物
TW201718582A (zh) 用於發炎、自體免疫及/或增生性疾病之治療之新穎化合物及其醫藥組合物
JP2020507612A (ja) Ｉｒａｋ阻害剤及びｊａｋ阻害剤を含む抗炎症組成物
TW202502765A (zh) 一種prmt5抑制劑、其製備方法及應用
KR20160104730A (ko) 벤즈이미다졸 유도체 및 염증 질환의 치료를 위한 그의 약학 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230327

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240611

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241203